Investigational RNAi Therapeutic Targeting C5 Is Efficacious in Pre-clinical Models of Myasthenia Gravis-Reference-Cited by-同舟云学术

Investigational RNAi Therapeutic Targeting C5 Is Efficacious in Pre-clinical Models of Myasthenia Gravis

Published:2019-06 Issue: Volume:13 Page:484-492
ISSN:2329-0501
Container-title:Molecular Therapy - Methods & Clinical Development
language:en
Short-container-title:Molecular Therapy - Methods & Clinical Development

Author:

Kusner Linda L.,Yucius Kristina,Sengupta Manjistha,Sprague Andrew G.,Desai Dhruv,Nguyen Tuyen,Charisse Klaus,Kuchimanchi Satya,Kallanthottathil Rajeev,Fitzgerald Kevin,Kaminski Henry J.,Borodovsky Anna

Publisher

Elsevier BV

Subject

Genetics,Molecular Biology,Molecular Medicine

Reference31 articles.

1. [Myasthenia gravis and autoantibodies: Pathophysiology of the different subtypes];Berrih-Aknin;Rev. Med. Interne,2014

2. Ultrastructural localization of immune complexes (IgG and C3) at the end-plate in experimental autoimmune myasthenia gravis;Sahashi;J. Neuropathol. Exp. Neurol.,1978

3. Ultrastructural localization of the terminal and lytic ninth complement component (C9) at the motor end-plate in myasthenia gravis;Sahashi;J. Neuropathol. Exp. Neurol.,1980

4. Myasthenia gravis: quantitative immunocytochemical analysis of inflammatory cells and detection of complement membrane attack complex at the end-plate in 30 patients;Nakano;Neurology,1993

5. Standardization of the experimental autoimmune myasthenia gravis (EAMG) model by immunization of rats with Torpedo californica acetylcholine receptors: Recommendations for methods and experimental designs;Losen;Exp. Neurol.,2015

Cited by 40 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Myasthenia gravis: the future is here;Journal of Clinical Investigation;2024-06-17

2. Targeting autoimmune mechanisms by precision medicine in Myasthenia Gravis;Frontiers in Immunology;2024-06-06

3. Development of the Complement C5 Assay by LC–MS/MS in Monkey Serum and Comparison with Enzyme-Linked Immunosorbent Assay;ACS Omega;2024-01-31

4. Chemically Modified Platforms for Better RNA Therapeutics;Chemical Reviews;2024-01-29

5. Myasthenia gravis: the changing treatment landscape in the era of molecular therapies;Nature Reviews Neurology;2024-01-08